Raynaud's phenomenon secondary to erenumab in a patient with chronic migraine
© 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd..
Raynaud's phenomenon is a rare side effect of CGRP monoclonal antibodies. These molecular treatments are a relatively new class of drugs for the prevention of migraine. It is likely that we will see this side effect more often in the future. Patients with a background of Raynaud's phenomenon may experience worsening of their symptoms if started on these treatments.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Clinical case reports - 9(2021), 8 vom: 01. Aug., Seite e04625 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Manickam, Agaath Hedina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CGRP monoclonal antibodies |
|---|
| Anmerkungen: |
Date Revised 03.04.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1002/ccr3.4625 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329732277 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329732277 | ||
| 003 | DE-627 | ||
| 005 | 20240403233000.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ccr3.4625 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1362.xml |
| 035 | |a (DE-627)NLM329732277 | ||
| 035 | |a (NLM)34430000 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Manickam, Agaath Hedina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Raynaud's phenomenon secondary to erenumab in a patient with chronic migraine |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 03.04.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. | ||
| 520 | |a Raynaud's phenomenon is a rare side effect of CGRP monoclonal antibodies. These molecular treatments are a relatively new class of drugs for the prevention of migraine. It is likely that we will see this side effect more often in the future. Patients with a background of Raynaud's phenomenon may experience worsening of their symptoms if started on these treatments | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a CGRP monoclonal antibodies | |
| 650 | 4 | |a Raynaud's phenomenon | |
| 650 | 4 | |a chronic migraine | |
| 650 | 4 | |a erenumab | |
| 700 | 1 | |a Buture, Alina |e verfasserin |4 aut | |
| 700 | 1 | |a Tomkins, Esther |e verfasserin |4 aut | |
| 700 | 1 | |a Ruttledge, Martin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical case reports |d 2013 |g 9(2021), 8 vom: 01. Aug., Seite e04625 |w (DE-627)NLM234405864 |x 2050-0904 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2021 |g number:8 |g day:01 |g month:08 |g pages:e04625 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ccr3.4625 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2021 |e 8 |b 01 |c 08 |h e04625 | ||